Molecular Transport Medium Market size was over USD 1.01 Billion in 2023 and is set to cross USD 1.16 Billion by the end of 2036, growing at more than 1.1% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of molecular transport medium is estimated at USD 1.02 Billion.The growth of the market can be attributed to the rising number of experiments at labs and research institutions. The world was being prepared for pandemics for a prolonged time where countless clinical trials were being conducted to develop treatment and diagnosis solution for infectious diseases. The percentage of research and development expenditure (in % GDP) was 2.63% in 2020, up from 2.13% in 2017. Government of various nation are spending notable sum on the development of molecular transportation medium since it is the best medium to gather medical samples without endangering the lives of healthcare providers.
In addition to these, global molecular transport medium market trends such as, rowing adoption of transport mediums for infectious disorders and rising awareness regarding the early detection of viral diseases compelling governments to initiate management measures to prevent outbreaks of these infections are further expected to influence the market growth positively over the forecast period. The U.S. funding for global health security for the fiscal year 2021 was estimated to reach approximately USD 10 billion up from around USD 1 billion in 2001-11. Also, additional funding was provided for the emergency outbreaks of Ebola and the Zika virus. Hence, all these factors are estimated to propel the market growth over the forecast period.
Growth Drivers
Challenges
|
Base Year |
2023 |
|
Forecast Year |
2024-2036 |
|
CAGR |
1.1% |
|
Base Year Market Size (2023) |
USD 1.01 Billion |
|
Forecast Year Market Size (2035) |
USD 1.16 Billion |
|
Regional Scope |
|
Type (Viral Transportation Medium, Virus Swabs)
The global molecular transport medium market is segmented and analyzed for demand and supply by type into viral transportation medium and virus swabs. Between these two types, the viral transportation medium segment is estimated to gain the largest market share over the projected time frame. The growth of the segment can be attributed to the sudden break out of the COVID-19 pandemic triggering the demand for transport medium products and kits worldwide. According to the Journal of Clinical Microbiology between 3000 to 5000 viral transport medium tubes are produced each day to support SARS-CoV-2 PCR testing globally. The innovation of kits containing vials, double-ended flocked swabs, antibiotics, and other antibacterial and antifungal items that prevent contamination is estimated to drive the segment growth.
Application (Diagnostic Laboratories, Microbiology Laboratories, Hospitals & Clinics)
The global molecular transport medium market is also segmented and analyzed for demand and supply by application into diagnostic laboratories, microbiology laboratories, hospitals & clinics, and others. Amongst these three segments, the diagnostic laboratories segment is expected to garner a significant share. The growth of this segment can be attributed to the surge in clinical trials and diagnostic testes backed by the rising awareness of early diagnosis in the global population. The higher prevalence of severe infectious diseases across the globe has spurred the demand for molecular transport medium worldwide. It was observed that in the United States, over 6 billion diagnostic tests are performed annually.
Our in-depth analysis of the global market includes the following segments:
|
By Type |
|
|
By Application |
|
|
By Indication |
|
North American Market Forecast
The North American molecular transport medium market, amongst the market in all the other regions, is projected to hold the largest market share by the end of 2036. The growth of the market can be attributed majorly to the improvement in the availability of new diagnostic test kits and drugs in pharmacies and retail shops as OTC drugs. As of December 2021, approximately 300 million at-home rapid test kits were available in the market in the U.S. which reached nearly 24 million in August 2021. Additionally, the rise in the number of infections, parasitic diseases coupled with increase in the manufacturing capacity of vaccines and drugs is estimated to boost the regional market growth during the forecast period. For instance, COVID-19 vaccine manufacturing was estimated to hit around 7 million doses in 2021 with the production rate of around 1 billion doses per month by vaccine manufacturers across the world. The recall was done to reduce the false positive test results, unnecessary quarantine, and treatment with antivirals.
APAC Market Statistics
Furthermore, the market in the Asia Pacific is also estimated to witness noteworthy growth opportunity over the forecast period. Rising cases of infectious diseases such as, COVID-19, Lyme Disease, TB, and others backed by the boom in the population along with significant number of geriatrics in the region are estimated to be major factors to expand the market size over the forecast period. In Asia Pacific, preventable infections are considered to be one of the major causes of death that is anticipated to boost the demand for molecular transport medium for collecting samples. Therefore, all these factors are anticipated to boost the market growth over the forecast period.
Thermo Fisher Scientific Inc is offering In Vitro Diagnostic Requirements (IVDR) versions to help molecular diagnostic manufacturers to adopt higher standards. The demand for IVDR is growing on account of growing awareness for quick clinically relevant Oncology biomarkers identification and in the diagnosis of multiple-infectious pathogens. It is going to be huge help for healthcare providers to make serious treatment decisions associated with infection diseases, cancer, and others.
Becton, Dickinson and Company to introduce a new high throughout molecular diagnostic combination test, BD MAX, for SARS-CoV-2 and Influenza A/B, the second test for BD COR have been CE marked to the IVD directive. In this test, a single nasopharyngeal swab sample are used to identify if the patients have flu, COVID-19, or RSV.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?